New yellow fever vaccine matches safety and effectiveness of current shot

Yellow fever is a viral disease that is spread to humans through the bites of infected mosquitoes. The symptoms range from ...
MedPage Today

Next-Gen Yellow Fever Vaccine Hits the Mark in Mid-Stage Trial

"The investigational vYF vaccine is a next-generation, live-attenuated yellow fever vaccine grown in serum-free Vero cells ...
The News International

New yellow fever vaccine proves as safe and effective : A complete guide

A promising new weapon in the global fight against yellow fever has emerged. Spread to humans through the bites of infected ...
Nasdaq

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV ...

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data ...
Seeking Alpha

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

--Vaxcyte, Inc., a clinical-stage vaccine innovation company, today provided updates on the continued advancement of VAX-31, the Company’ s next-generation 31- valent pneumococcal conjugate vaccine ...

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on ...